J2351 — Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
J2351 is a HCPCS Level II code for injection, ocrelizumab, 1 mg and hyaluronidase-ocsq. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
Medically Unlikely Edits — units per day
The most units of J2351 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 920 units MAI 3 — Date of Service Edit: Clinical · Prescribing Information
- outpatient
- 920 units MAI 3 — Date of Service Edit: Clinical · Prescribing Information
- DME supplier
- 920 units MAI 3 — Date of Service Edit: Clinical · Prescribing Information
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.
The CMS record for J2351
- Long descriptor
- Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq
- Short descriptor
- Inj ocrelizumab 1mg hya-ocsq
- Added
- April 1, 2025
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J2351
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J2351 is not quite right, the correct code is very often within a few positions of it.
- J2315Injection, naltrexone, depot form, 1 mg
- J2320Injection, nandrolone decanoate, up to 50 mg
- J2323Injection, natalizumab, 1 mg
- J2325Injection, nesiritide, 0.1 mg
- J2326Injection, nusinersen, 0.1 mg
- J2327Injection, risankizumab-rzaa, intravenous, 1 mg
- J2329Injection, ublituximab-xiiy, 1mg
- J2350Injection, ocrelizumab, 1 mg
- J2353Injection, octreotide, depot form for intramuscular injection, 1 mg
- J2354Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
- J2355Injection, oprelvekin, 5 mg
- J2356Injection, tezepelumab-ekko, 1 mg
- J2357Injection, omalizumab, 5 mg
- J2358Injection, olanzapine, long-acting, 1 mg
- J2359Injection, olanzapine, 0.5 mg
- J2360Injection, orphenadrine citrate, up to 60 mg
Questions about J2351
What is HCPCS code J2351?
J2351 is a HCPCS Level II code for injection, ocrelizumab, 1 mg and hyaluronidase-ocsq. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J2351?
The CMS HCPCS file marks J2351 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J2351 paid under the physician fee schedule?
J2351 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).